Lv647
2000 积分 2020-09-22 加入
Cost-effectiveness of anlotinib vs. pembrolizumab and nivolumab as third-line treatment in recurrent small cell lung cancer in China
3天前
已完结
Quality of life results from a randomized, double-blinded, placebo-controlled, multi-center phase III trial of anlotinib in patients with advanced non-small cell lung cancer
3天前
已完结
Hand-foot syndrome and survival in patients with advanced non-small-cell lung cancer receiving anlotinib: a subgroup analysis of data from the ALTER 0303 study
3天前
已完结
Anlotinib as third- or further-line therapy for short-term relapsed small-cell lung cancer: subgroup analysis of a randomized phase 2 study (ALTER1202)
3天前
已完结
Benmelstobart With or Without Anlotinib After Chemoradiotherapy for Unresectable Non−Small Cell Lung Cancer: The R-ALPS Randomized Clinical Trial
3天前
待确认
Bridging EGFR/TGF-β Signaling to Bypass Resistance to Immune Checkpoint Blockade
19天前
已完结
Risk Factors for Immune Checkpoint Inhibitor-Related Pneumonitis in Cancer Patients: A Systemic Review and Meta-Analysis
24天前
已完结
Spatial transcriptomics of primary and metastatic ALK-rearranged NSCLC reveals site-specific adaptations
2个月前
已完结
Clinical usability of an explainable AI decision support tool and evaluation of multimodal models in NSCLC
2个月前
已完结
DRMref: comprehensive reference map of drug resistance mechanisms in human cancer
2个月前
已完结